Standout Papers

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis... 2021 2026 2022 2024321
  1. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis (2022)
    Eric L. Simpson, Kim Papp et al. JAMA Dermatology
  2. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (2021)
    Emma Guttman‐Yassky, Henrique D. Teixeira et al. The Lancet

Immediate Impact

1 from Science/Nature 70 standout
Sub-graph 1 of 21

Citing Papers

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
2024 Standout
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
2024 Standout
2 intermediate papers

Works of Brian Calimlim being referenced

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
2016
The Impact of Uncontrolled Asthma on Absenteeism and Health-Related Quality of Life
2009

Author Peers

Author Last Decade Papers Cites
Brian Calimlim 730 446 288 66 1.3k
Peter Anderson 264 199 287 49 1.3k
Mandeep Kaur 862 293 201 98 1.6k
I. Zschocke 633 153 123 57 1.3k
Usha G. Mallya 307 212 167 49 996
Ronit Confino‐Cohen 420 677 243 71 1.6k
Amy Mulick 315 216 157 56 1.5k
Kevin R. Patel 1325 791 442 50 1.6k
S.E. Marrón 1040 224 128 55 1.4k
Brad Shumel 838 709 448 58 1.2k
Rukmini Rajagopalan 492 283 92 47 1.2k

All Works

Loading papers...

Rankless by CCL
2026